Evidence map›Paper›PMID 41935424›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2026

Aryl hydrocarbon receptor ligand 6-formylindolo[3,2-b]carbazole attenuates pressure overload cardiac hypertrophy by activating the CYP1A1/19(S)-hydroxyeicosatetraenoic acid (HETE) and suppressing midchain-HETEs/G protein coupled receptor 31 pathways.

Ahmad H Alammari, Shereen M Hamza, Fadumo Ahmed Isse, Keshav Gopal, John R Ussher, Ayman O S El-Kadi

Abstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmad H AlammariFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
Shereen M HamzaFaculty of Medicine & Dentistry, Physiology Department, University of Alberta, Edmonton, Alberta, Canada.
Fadumo Ahmed IsseFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
Keshav GopalFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
John R UssherFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada; Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada.
Ayman O S El-KadiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada; Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada. Electronic address: aelkadi@ualberta.cadx.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pressure overload induced cardiac hypertrophy is a major contributor to heart failure, and the arachidonic acid (AA) metabolism through cytochrome P450 enzymes is one of the metabolic pathways implicated in the hypertrophic response. The aryl hydrocarbon receptor (AhR) regulates CYP1A1 and CYP1B1 that generate protective 19-hydroxyeicosatetraenoic (HETE) and hypertrophic midchain-HETEs eicosanoids, respectively. The endogenous AhR ligand 6-formylindolo[3,2-b]carbazole (FICZ) is a potent and selective inducer of CYP1A1, but its role in pressure overload induced cardiac hypertrophy has not been examined. This study investigated whether daily AhR activation by FICZ alters AA metabolites and attenuates cardiac hypertrophy in the abdominal aortic constriction (AAC) model. Male Sprague-Dawley rats underwent AAC or sham surgery and received FICZ (0.2 mg/kg per day) for 5 weeks. Echocardiography was performed at baseline and 5 weeks post-AAC, and gene, protein, and midchain-HETEs levels were assessed by real-time polymerase chain reaction, western blot, and liquid chromatography-tandem mass spectrometry, respectively. FICZ significantly reduced AAC-induced increases in left ventricular mass, ventricular wall thickness, heart weight-to-tibial length ratio, and hypertrophic gene expression. FICZ produced selective induction of CYP1A1 and significant rise in cardiac 19(S)-HETE. AAC significantly increased CYP1B1 and 12-LOX protein expressions and midchain-HETEs, whereas FICZ significantly attenuated 12-LOX and midchain-HETE. AAC also upregulated G protein coupled receptor 31, and FICZ reduced this increase at both mRNA and protein levels. This study provides the first evidence that endogenously generated 19(S)-HETE is cardioprotective in a pressure overload model and identifies FICZ as a modulator of the CYP1A1/19(S)-HETE that suppresses midchain-HETEs/G protein coupled receptor 31 pathways. SIGNIFICANT STATEMENT: This study demonstrates that 6-formylindolo[3,2-b]carbazole protect against cardiac hypertrophy induced by abdominal aortic constriction in rats. The significance of this research lies in its novel discovery, which elucidates for the first time the involvement of G protein coupled receptor 31 and the induction of CYP1A1 and 19-hydroxyeicosatetraenoic acid and suppressing midchain-hydroxyeicosatetraenoic acid/G protein coupled receptor 31 pathways by 6-formylindolo[3,2-b]carbazole in the protection against pressure overload cardiac hypertrophy in rats.

Indexed as

CarbazolesCardiomegalyCytochrome P-450 CYP1A1Hydroxyeicosatetraenoic AcidsReceptors, Aryl HydrocarbonReceptors, G-Protein-CoupledAnimalsCytochrome P-450 CYP1B1LigandsMaleRatsRats, Sprague-DawleySignal Transduction19-hydroxy-5,8,11,14-eicosatetraenoic acid6-formylindolo(3,2-b)carbazoleCarbazolesCytochrome P-450 CYP1A1Cytochrome P-450 CYP1B1Hydroxyeicosatetraenoic AcidsLigandsReceptors, Aryl HydrocarbonReceptors, G-Protein-Coupled19-hydroxyeicosatetraenoic6-Formylindolo[3,2-b]carbazoleAbdominal aortic constrictionCardiac hypertrophyCYP1A1G Protein coupled receptor 31

Identifiers

PMID41935424
PMCPMC13197958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.